Supplement

You have full text access to this OnlineOpen article

Defining a global research agenda for breast cancer†

  1. Richard R. Love MD‡,*

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23831

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2366–2371, 15 October 2008

Additional Information

How to Cite

Love, R. R. (2008), Defining a global research agenda for breast cancer. Cancer, 113: 2366–2371. doi: 10.1002/cncr.23831

Author Information

  1. Department of Internal Medicine, Division of Hematology/Oncology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  1. ‡

    Fax: (614) 293-7526

*Department of Internal Medicine, Division of Hematology/Oncology, Ohio State University Comprehensive Cancer Center, B402 Starling Loving Hall, 320 W. 10th Avenue, Columbus, Ohio 43210

  1. †

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008

Funded by

  • NIH/NCI. Grant Numbers: CA064339, CA097375
  • The Breast Cancer Research Foundation
  • The International Breast Cancer Research Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (86K)

REFERENCES

  • 1
    Hermon C,Beral V. Breast cancer mortality rates are leveling off or beginning to decline. Br J Cancer. 1996; 73: 955–960.
  • 2
    Peto R. Mortality from breast cancer in the UK has decreased suddenly. BMJ. 1998; 317: 476–478.
  • 3
    Peto R,Boreham J,Clarke M,Davies C,Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000; 355: 1822.
  • 4
    Bray F,McCarron P. Parkin DM. The changing global patterns of female breast cancer mortality. Breast Cancer Res Treat. 2004; 6: 229–239.
  • 5
    Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006; 17( suppl 8): 15–23.
  • 6
    Ferlay J,Bray F,Pisani P,Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, version 1.0. IARC CancerBase No. 5. Lyon, France: IARC Press; 2001.
  • 7
    CuradoMP,EdwardsB,ShinHR, eds. Cancer Incidence in Five Continents, Vol IX. IARC Scientific Publications No. 160. Lyon, France: IARC Press; 2007.
  • 8
    Porter P. “Westernizing” women's risks? Breast cancer in lower-income countries. N Engl J Med. 2008; 358: 213–216.
  • 9
    World Cancer Research Fund. Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
  • 10
    Farmer P. Pathologies of Power. Berkeley: University of California Press; 2005.
  • 11
    Yunus M,Weber K. Creating a world without poverty: social business and the future of capitalism. Public Affairs. 2008: 107.
  • 12
    Mourali N,Muenz LR,Tabbane F,Belhassen S,Bahi J,Levine PH. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980; 46: 2741–2746.
    Direct Link:
  • 13
    Ikpatt OF,Xu J,Kramtsov A,Ndoma-Egba R,Perou C,Olopade O. Hormone receptor negative and basal-like subtypes are overrepresented in invasive breast carcinoma from women of African ancestry [abstract]. AACR Meeting Abstracts. 2005: 598–599.
  • 14
    Anderson WF,Chatterjee N,Ershler WB,Brawley OW. Estrogen receptor breast cancer phenotypes on the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002; 76: 27–36.
  • 15
    Pegoraro RJ,Karnan V,Nirmul D,Joubert SM. Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res. 1986; 46(4 pt 2): 2117–2120.
  • 16
    Uy GB,Laudico AV,Fernandez AM, et al. Immunohistochemical assay of hormone receptors in breast cancer at the Philippine General Hospital: Importance of early fixation of specimens. Philipp J Surg Spec. 2007; 62: 123–127.
  • 17
    Love RR,Duc NB,Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002; 20: 2559–2566.
  • 18
    Goetz MP,Rae JM,Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005; 23: 9312–9318.
  • 19
    Desta Z,Flockhart DA. Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Onc. 2007; 33: 5147–5149.
  • 20
    Beith JM,Goh BC,Yeo W, et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002: 21. Abstract 252.
  • 21
    Fan L,Guo JY,Wong CI, et al. Genetic variants in human carbonyl reductase 3 (CBR3) and their influence on doxorubicin pharmacokinetics in Asian breast cancer patients. J Clin Onc. 2007; 25( suppl 2505). ASCO Annual Meeting Proceedings pt 1; No. 185.
  • 22
    Bonadonna G,Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304: 10–15.
  • 23
    Leventhal H,Nerenz D,Steele D. Illness representations and coping with health threats. In: BaumA,SingerJ, eds. A Handbook of Psychology and Health. Hillsdale, NJ: Erlbaum; 1984: 219–252.
  • 24
    Harford J,Azevedo E,Fischietto M. Breast healthcare guideline implementation in low- and middle-income countries (LMCs): breast program resource allocation. Cancer. 2008; 113( 8 suppl): 2282–2296.
    Direct Link:
  • 25
    Auerbach AD,Landefeld CS,Shojania KG. The tension between needing to improve care and knowing how to do it. N Engl J Med. 2007; 357: 608–613.
  • 26
    Steinbrook R. Closing the affordability gap for drugs in low-income countries. N Engl J Med. 2007; 357: 1996–1999.
  • 27
    Bines J,Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment. Cancer. 2008; 113( 8 suppl): 2353–2358.
    Direct Link:
  • 28
    Berry DA,Cronin KA,Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784–1792.
  • 29
    Commission on Macroeconomics and Health. Macroeconomics and Health: Investing In Health For Economic Development. Geneva: World Health Organization; 2001.
  • 30
    StewartBW,KleihuisP, eds. World Cancer Report. Lyons, France: International Agency for Research on Cancer (IARC); 2003.
  • 31
    Thomas DB,Gao DL,Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002; 94: 1445–1457.
  • 32
    Semiglazov VF,Sagaidak VN,Moiseyenko VM,Mikhailov EA. Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian Federation/World Health Organization Study. Eur J Cancer. 1993; 29A: 2039–2046.
  • 33
    Pisani P,Parkin DM,Ngelangel C, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer. 2006; 118: 149–154.
    Direct Link:
  • 34
    IARC Handbook on Cancer Prevention, Vol 7. Breast Cancer Screening. Lyon, France: IARC Press; 2002.
  • 35
    Collier P. The Bottom Billion. Oxford, England: Oxford University Press; 2007.
  • 36
    Institute of Medicine. Cancer control opportunities in low and middle income countries. Washington, DC: National Academies Press; 2007.
  • 37
    Mellstedt H. Cancer initiatives in developing countries. Ann Oncol. 2006; 17( suppl 8): 24–31.
  • 38
    Personal communication from AB Miller to RR Love. November 24, 2007.
  • 39
    Love RR,Van Dinh N,Quy TT, et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol. 2008; 26: 253–257.
  • 40
    Epstein H,Kim J. AIDS and the power of women. The New York Review of Books. February 15, 2007.
  • 41
    Rastogi T,Hildesheim A,Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer. 2004; 4: 909–917.
  • 42
    Caffarella R,Kamis M. Walk farther, view broader (Jauh Berjalan, Luas Pandangan): Malaysian Breast Cancer Education. Presented at the first National Summit on Breast Cancer Education, Kuala Lumpur, Malaysia. June 30–July 2, 2006.
  • 43
    Campbell C. Letting Them Die: Why AIDS Prevention Programmes Fail (African Issues). Oxford, England: The International African Institute/James Curry; 2003.
View Full Article (HTML) Get PDF (86K)